R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to confirm the efficacy of the association of R-2cda in
patients affected by Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma and of
evaluating the efficacy of prolongation of therapy with additional infusions of Rituximab
alone in increasing and prolonging the duration of the response.